Characterization of ABT-494, a Second Generation Jak1 Selective Inhibitor.

被引：0

作者：

Graff, Candace ^{[1
]}

Schwartz, Annette ^{[1
]}

Voss, Jeffrey ^{[2
]}

Wishart, Neil ^{[2
]}

Olson, Lisa ^{[1
]}

George, Jonathon ^{[2
]}

Hyland, Deborah ^{[2
]}

Camp, Heidi ^{[3
]}

机构：

[1] AbbVie Inc, AbbVie Biores Ctr, Worcester, MA USA

[2] AbbVie Pharmaceut, Worcester, MA USA

[3] Abbvie, Winnetka, IL USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2014年 / 66卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1499

引用

页码：S659 / S660

页数：2

共 50 条

[31] Design of a potent and selective dual JAK1/TYK2 inhibitor
Mammoliti, Oscar
Menet, Christel
Cottereaux, Celine
Blanc, Javier
De Blieck, Ann
Coti, Ghjuvanni
Geney, Raphael
Oste, Line
Ostyn, Koen
Palisse, Adeline
Quinton, Evelyne
Schmitt, Benoit
Borgonovi, Monica
Parent, Isabelle
Jagerschmidt, Catherine
De Vos, Steve
Vayssiere, Beatrice
Lopez-Ramos, Miriam
Shoji, Kenji
Brys, Reginald
Amantini, David
Galien, Rene
Joannesse, Caroline
BIOORGANIC & MEDICINAL CHEMISTRY, 2024, 114
[32] Dosing Strategy for Itacitinib, a Selective JAK1 Inhibitor, for the Treatment of Ulcerative Colitis
Barbour, April
Zhang, Yan
Punwani, Naresh
Diamond, Sharon
Chen, Xuejun
Yeleswaram, Swamy
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S136 - S136
[33] A JAK1 Selective Kinase Inhibitor and Tofacitinib Affect Macrophage Activation and Function
De Vries, L. C. S.
Duarte, J. M.
de Krijger, M.
Welting, O.
van Harnersveld, P. H. P.
Van Leeuwen-Hilbers, F. W. M.
Moerland, P. D.
Jongejan, A.
D'Haens, G. R.
De Jonge, W. J.
Wildenberg, M. E.
INFLAMMATORY BOWEL DISEASES, 2019, 25 (04) : 647 - 660
[34] Discovery of CYT387: A potent and selective dual inhibitor of JAK1 and JAK2
Burns, Christopher J.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
[35] Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases
Covington, Maryanne
He, Xin
Scuron, Monika
Li, Jun
Collins, Robert
Juvekar, Ashish
Shin, Niu
Favata, Margaret
Gallagher, Karen
Sarah, Sarala
Xue, Chu-biao
Peel, Michael
Burke, Krista
Oliver, Julian
Fay, Brittany
Yao, Wenqing
Huang, Taisheng
Scherle, Peggy
Diamond, Sharon
Newton, Robert
Zhang, Yan
Smith, Paul
EUROPEAN JOURNAL OF PHARMACOLOGY, 2020, 885
[36] JAK1 selective inhibitors for the treatment of spondyloarthropathies
White, Jonathan P. E.
Coates, Laura C.
RHEUMATOLOGY, 2021, 60 : II39 - II44
[37] JAK1 selective inhibitors for the treatment of spondyloarthropathies
White, Jonathan P. E.
Coates, Laura C.
RHEUMATOLOGY, 2021, 60 (SUPPL 2) : ii39 - ii44
[38] Pharmacokinetic characteristics of golidocitinib, a highly selective JAK1 inhibitor, in healthy adult participants
Chen, Kan
Guan, Xiaoduo
Yang, Zhenfan
Zhou, Yue
Liu, Ziyi
Deng, Xueyuan
Liu, Donghong
Hu, Pei
Chen, Rui
FRONTIERS IN IMMUNOLOGY, 2023, 14
[39] Identification and Biological Evaluation of a Potent and Selective JAK1 Inhibitor for the Treatment of Pulmonary Fibrosis
Park, Eunsun
Park, Seolhee
Lee, Sun Joo
Jeong, Dayeon
Jin, Hee
Moon, Heegyum
Cha, Boksik
Kim, Dayea
Ma, Seonghee
Seo, Wonhyo
Han, Seung-Hee
Lee, Yun-Sil
Kang, Soosung
JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (23) : 16342 - 16363
[40] Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
Quintas-Cardama, Alfonso
Vaddi, Kris
Liu, Phillip
Manshouri, Taghi
Li, Jun
Scherle, Peggy A.
Caulder, Eian
Wen, Xiaoming
Li, Yanlong
Waeltz, Paul
Rupar, Mark
Burn, Timothy
Lo, Yvonne
Kelley, Jennifer
Covington, Maryanne
Shepard, Stacey
Rodgers, James D.
Haley, Patrick
Kantarjian, Hagop
Fridman, Jordan S.
Verstovsek, Srdan
BLOOD, 2010, 115 (15) : 3109 - 3117

← 1 2 3 4 5 →